Lilly Antibody Proves Ineffective In Rheumatoid Arthritis, But Lupus Trials Continue
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly has stopped one Phase III rheumatoid arthritis trial for its anti-BAFF antibody tabalumab and ceased enrollment in two others after a mid-term analysis revealed a lack of efficacy, but the company is soldiering on with a Phase III program in lupus erythematosus.